YD Bio (NASDAQ:YDES) Upgraded by Wall Street Zen to Hold Rating

YD Bio (NASDAQ:YDES) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of YD Bio in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

YD Bio Price Performance

Shares of YDES stock opened at $8.58 on Friday. The stock’s fifty day moving average price is $11.05. YD Bio has a 12 month low of $7.20 and a 12 month high of $25.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in YD Bio stock. Geode Capital Management LLC boosted its holdings in YD Bio Limited (NASDAQ:YDES) by 10.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,363 shares of the biotechnology company’s stock after purchasing an additional 5,292 shares during the quarter. Geode Capital Management LLC owned approximately 0.08% of YD Bio worth $711,000 at the end of the most recent quarter.

YD Bio Company Profile

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.